Sirolimus-loaded polymeric micelles with honokiol for oral delivery

Journal of Pharmacy and Pharmacology

Volumn 67, Issue 12, 2015, Pages 1663-1672

  Li, Xinru ^a   Hou, Xucheng ^b   Ding, Weiming ^b   Cong, Shuangchen ^a   Zhang, Yuanyuan ^a   Chen, Mengmeng ^a   Meng, Yansha ^a   Lei, Jiongxi ^a   Liu, Yan ^a   Li, Guiling ^b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

honokiol; oral delivery; polymeric micelle; sirolimus; transport

Indexed keywords

HONOKIOL; MULTIDRUG RESISTANCE PROTEIN; POLYMER; RAPAMYCIN; ABCB1 PROTEIN, HUMAN; BIPHENYL DERIVATIVE; DRUG CARRIER; LIGNAN; MACROGOL DERIVATIVE; METHOXY POLY(ETHYLENE GLYCOL)-POLY(LACTIDE); MICELLE; POLYESTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CACO 2 CELL LINE; CELL TRANSPORT; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TRANSPORT; ENCAPSULATION; FLOW CYTOMETRY; INTESTINE FLUID; MALE; MICELLE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; CACO-2 CELL LINE; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG STABILITY; HUMAN; INTESTINE ABSORPTION; INTESTINE MUCOSA; JEJUNUM; KINETICS; MEDICINAL CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; PERMEABILITY; SOLUBILITY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BIPHENYL COMPOUNDS; CACO-2 CELLS; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG STABILITY; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; JEJUNUM; KINETICS; LIGNANS; MALE; MICELLES; P-GLYCOPROTEINS; PARTICLE SIZE; PERMEABILITY; POLYESTERS; POLYETHYLENE GLYCOLS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; SOLUBILITY;

EID: 84954531986     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12482     Document Type: Article

References (55)

1. Vezina C, et al. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975; 28: 721-726.
2. Martel RR, et al. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977; 55: 48-51.
3. Rial Mdel C, et al. Individualizing early use of sirolimus in renal transplantation. Transplant Proc 2010; 42: 4518-4525.
4. Toso C, et al. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51: 1237-1243.
5. Shen LJ, Wu FL,. Nanomedicines in renal transplant rejection-focus on sirolimus. Int J Nanomedicine 2007; 2: 25-32.
6. Vasquez EM,. Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health Syst Pharm 2000; 57: 437-448, quiz 449-451.
7. Simamora P, et al. Solubilization of rapamycin. Int J Pharm 2001; 213: 25-29.
8. Rouf MA, et al. Rapamycin-cyclodextrin complexation: improved solubility and dissolution rate. J Incl Phenom Macrocycl Chem 2011; 70: 167-175.
9. Kim MS, et al. Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int J Nanomedicine 2011; 6: 2997-3009.
10. Cho W, et al. Optimized formulation of solid self-microemulsifying sirolimus delivery systems. Int J Nanomedicine 2013; 8: 1673-1682.
11. Rosen H, Abribat T,. The rise and rise of drug delivery. Nat Rev Drug Discov 2005; 4: 381-385.
12. Alemdar AY, et al. Liposomal formulations of tacrolimus and rapamycin increase graft survival and fiber outgrowth of dopaminergic grafts. Cell Transplant 2004; 13: 263-271.
13. Lemahieu WP, et al. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Am J Transplant 2004; 4: 1514-1522.
14. Anglicheau D, et al. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 2006; 70: 1019-1025.
15. Cummins CL, et al. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther 2004; 308: 143-155.
16. Dean M, et al. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001; 42: 1007-1017.
17. Pastan I, et al. Molecular manipulations of the multidrug transporter: a new role for transgenic mice. FASEB J 1991; 5: 2523-2528.
18. Silverman JA, Schrenk D,. Hepatic canalicular membrane 4: expression of the multidrug resistance genes in the liver. FASEB J 1997; 11: 308-313.
19. Lee CG, Gottesman MM,. HIV-1 protease inhibitors and the MDR1 multidrug transporter. J Clin Invest 1998; 101: 287-288.
20. Thiebaut F, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987; 84: 7735-7738.
21. Breedveld P, et al. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 2006; 27: 17-24.
22. Singh DV, et al. A plausible explanation for enhanced bioavailability of P-gp substrates in presence of piperine: simulation for next generation of P-gp inhibitors. J Mol Model 2013; 19: 227-238.
23. Gurunath S, et al. Oral bioavailability and intestinal absorption of candesartan cilexetil: role of naringin as P-glycoprotein inhibitor. Drug Dev Ind Pharm 2015; 41: 170-176.
24. Bansal T, et al. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur J Pharm Sci 2009; 36: 580-590.
25. Pyo MK, et al. Anti-platelet effect of the constituents isolated from the barks and fruits of Magnolia obovata. Arch Pharm Res 2002; 25: 325-328.
26. Park EJ, et al. Protective effects of honokiol and magnolol on tertiary butyl hydroperoxide- or D-galactosamine-induced toxicity in rat primary hepatocytes. Planta Med 2003; 69: 33-37.
27. Kuribara H, et al. Honokiol, a putative anxiolytic agent extracted from magnolia bark, has no diazepam-like side-effects in mice. J Pharm Pharmacol 1999; 51: 97-103.
28. Park J, et al. In vitro antibacterial and anti-inflammatory effects of honokiol and magnolol against Propionibacterium sp. Eur J Pharmacol 2004; 496: 189-195.
29. Xu D, et al. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Cancer Lett 2006; 243: 274-280.
30. Yokoyama M, et al. Preparation of micelle-forming polymer-drug conjugates. Bioconjug Chem 1992; 3: 295-301.
31. Ale EC, et al. Ordered-disordered domain coexistence in ternary lipid monolayers activates sphingomyelinase by clearing ceramide from the active phase. Biochim Biophys Acta 2012; 1818: 2767-2776.
32. Mu CF, et al. The effects of mixed MPEG-PLA/Pluronic copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials 2010; 31: 2371-2379.
33. Zhang Y, et al. Cyclosporin A-loaded poly(ethylene glycol)-b-poly(d,l-lactic acid) micelles: preparation, in vitro and in vivo characterization and transport mechanism across the intestinal barrier. Mol Pharm 2010; 7: 1169-1182.
34. Dahmani FZ, et al. Enhanced oral bioavailability of paclitaxel in pluronic/LHR mixed polymeric micelles: preparation, in vitro and in vivo evaluation. Eur J Pharm Sci 2012; 47: 179-189.
35. Yao J, et al. Preparation of nobiletin in self-microemulsifying systems and its intestinal permeability in rats. J Pharm Pharm Sci 2008; 11: 22-29.
36. Song NN, et al. Intestinal permeability of metformin using single-pass intestinal perfusion in rats. World J Gastroenterol 2006; 12: 4064-4070.
37. Batrakova EV, et al. Effects of pluronic block copolymers on drug absorption in Caco-2 cell monolayers. Pharm Res 1998; 15: 850-855.
38. Rege BD, et al. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 2002; 16: 237-246.
39. Troutman MD, Thakker DR,. Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells. Pharm Res 2003; 20: 1192-1199.
40. Ma Y, Wink M,. Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells. Phytomedicine 2008; 15: 754-758.
41. Sznitowska M, et al. Paclitaxel solubility in aqueous dispersions and mixed micellar solutions of lecithin. Chem Pharm Bull (Tokyo) 2008; 56: 70-74.
42. Nikolsky E, et al. Impact of platelet glycoprotein IIb/IIIa receptor inhibitors on outcomes of diabetic patients undergoing percutaneous coronary interventions using sirolimus-eluting stents. Catheter Cardiovasc Interv 2008; 71: 896-906.
43. Malingre MM, et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 2001; 19: 1160-1166.
44. Yang S, et al. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res 2004; 21: 261-270.
45. Allen C, et al. Nano-engineering block copolymer aggregates for drug delivery. Colloids Surf B Biointerfaces 1999; 16: 3-27.
46. Li X, et al. Novel mixed polymeric micelles for enhancing delivery of anticancer drug and overcoming multidrug resistance in tumor cell lines simultaneously. Pharm Res 2010; 27: 1498-1511.
47. Balakrishnan P, et al. Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery. Int J Pharm 2009; 377: 1-8.
48. Li X, et al. Preparation and evaluation of novel mixed micelles as nanocarriers for intravenous delivery of propofol. Nanoscale Res Lett 2011; 6: 275.
49. Saravanakumar G, et al. Hydrotropic oligomer-conjugated glycol chitosan as a carrier of paclitaxel: synthesis, characterization, and in vivo biodistribution. J Control Release 2009; 140: 210-217.
50. Chen C, et al. Quercetin: a potential drug to reverse multidrug resistance. Life Sci 2010; 87: 333-338.
51. Shin SC, et al. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int J Pharm 2006; 313: 144-149.
52. Chaudhary PM, Roninson IB,. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993; 85: 632-639.
53. Herzog CE, et al. Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J Biol Chem 1993; 268: 2946-2952.
54. Bansal T, et al. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today 2009; 14: 1067-1074.
55. Li W, et al. Inhibition mechanism of P-glycoprotein mediated efflux by mPEG-PLA and influence of PLA chain length on P-glycoprotein inhibition activity. Mol Pharm 2013; 11: 71-80.